12 Aug '21
WESTPORT, Conn. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. , (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today issued the following letter to shareholders: Dear
28 Jul '21
-  Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets -  Additional clinical milestones and company progress anticipated throughout 2H 2021 and 2022 WESTPORT, Conn.
Displaying 1 - 10 of 19